A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \< 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.

NCT Number	NCT05622708
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Non-radiographic Axial Spondyloarthritis
Enrollment	240 participants
Start Date	2023-03-28
Primary Completion	2028-02-08 (estimated)
Study Completion	2028-04-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-20